Evidence map›Paper›PMID 36359506›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Early Assessment of Chemoradiotherapy Response for Locally Advanced Pancreatic Ductal Adenocarcinoma by Dynamic Contrast-Enhanced Ultrasound.

Xiu-Yun Lu, Xi Guo, Qi Zhang, Yi-Jie Qiu, Dan Zuo, Sheng Chen, Xiao-Fan Tian, Yu-Hong Zhou, Yi Dong, Wen-Ping Wang

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiu-Yun LuShanghai Institute of Medical Imaging, Shanghai 200032, China.
Xi GuoDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Qi ZhangDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yi-Jie QiuDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Dan ZuoDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Sheng ChenDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0000-0001-8946-0609
Xiao-Fan TianDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yu-Hong ZhouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yi DongDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0000-0002-0212-1477
Wen-Ping WangDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Sun Yat-sen University · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR4060, SHDC2020CR1031BNational Natural Science Foundation of China 82071942Shanghai Pujiang Program 2020PJD008
6 · The paper itself

Abstract

Objective: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) and quantitative parameters in early prediction of tumor response to chemoradiotherapy (CRT) in patients with locally advanced pancreatic ductal adenocarcinoma (LAPC). Patients and Methods: In this prospective study, patients with biopsy-proved and histopathologically proved LAPC who underwent regular CRT were recruited. DCE-US evaluations were performed before and four months after CRT. SonoVue-enhanced contrast-enhanced ultrasound (CEUS) was performed by an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, USA) equipped with a 5C1 MHz convex array transducer. Time−intensity curves were created by VueBox software (Bracco, Italy), and various DCE-US quantitative parameters were obtained. Taking Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomography (CT) or magnetic resonance imaging (MRI) as the gold standard, DCE-US parameters were compared between the treatment responder group (RG) and non-responder group (NRG). The correlation between the DCE-US parameters and the serum carbohydrate antigen 19-9 (CA 19-9) level was also analyzed. Results: Finally, 21 LAPC patients (mean age 59.3 ± 7.2 years) were included. In comparing the RG (n = 18) and NRG (n = 3), no significant change could be found among the mean size of the lesions (31.2 ± 8.1 mm vs. 27.2 ± 8.3 mm, p = 0.135). In comparing the TICs between the two groups, the LAPC lesions in the RG took a longer time to reach peak enhancement and to wash out. Among all the DCE-US parameters, RT (rise time), WiAUC (wash-in area under the curve), WoAUC (wash-out area under the curve) and WiWoAUC (wash-in and wash-out area under the curve) decreased significantly after CRT in the RG (p < 0.05). The RT ratio, WiAUC ratio, WoAUC ratio and WiWoAUC ratio were closely correlated with the change in serum CA 19-9 level in the RG (p < 0.05). Conclusion: DCE-US might be a potential imaging method for non-invasive follow-up for early response in LAPC patients treated by CRT.

Indexed as

chemoradiotherapy (CRT)dynamic contrast-enhanced ultrasound (DCE-US)locally advanced pancreatic ductal adenocarcinoma (LAPC)quantitative parameterstime–intensity curves (TICs)treatment response

Identifiers

PMID36359506
PMCPMC9689529
OpenAlexW4308772286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.